Literature DB >> 32047368

Psychopharmacology and Experimental Therapeutics for Bipolar Depression.

Manish K Jha1, James W Murrough1.   

Abstract

Bipolar disorder is a chronic illness that affects 2%-4% of U.S. adults during their lifetime. The course of bipolar disorder is commonly characterized by prolonged periods of depression interspersed with manic-hypomanic episodes. Management of depression among patients with bipolar disorder is challenging because of the limited number of medications currently approved by the Food and Drug Administration, the high proportion of patients who do not respond to these medications, and the metabolic and other side effects associated with long-term use of these medications. In addition to reviewing the clinical options available to patients with bipolar depression and their treatment providers, this article presents an evidence-based management approach and discusses the off-label uses of currently available treatments and experimental therapeutics under development. Copyright 2019 © by the American Psychiatric Association.

Entities:  

Keywords:  Drug treatment/psychopharmacology; Mood Disorders-Bipolar; bipolar depression; bipolar disorder; ketamine; mixed features; neurostimulation

Year:  2019        PMID: 32047368      PMCID: PMC6999209          DOI: 10.1176/appi.focus.20190009

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  65 in total

1.  Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

Authors:  Michael E Thase; Wayne Macfadden; Richard H Weisler; William Chang; Björn Paulsson; Arifulla Khan; Joseph R Calabrese
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

2.  Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison.

Authors:  Lori L Altshuler; Catherine A Sugar; Susan L McElroy; Brian Calimlim; Michael Gitlin; Paul E Keck; Ana Aquino-Elias; Brian E Martens; E Grace Fischer; Teri L English; Janine Roach; Trisha Suppes
Journal:  Am J Psychiatry       Date:  2017-01-31       Impact factor: 18.112

3.  Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III.

Authors:  Carlos Blanco; Wilson M Compton; Tulshi D Saha; Benjamin I Goldstein; W June Ruan; Boji Huang; Bridget F Grant
Journal:  J Psychiatr Res       Date:  2016-10-07       Impact factor: 4.791

4.  Transcranial direct current stimulation (tDCS) in unipolar vs. bipolar depressive disorder.

Authors:  A R Brunoni; R Ferrucci; M Bortolomasi; M Vergari; L Tadini; P S Boggio; M Giacopuzzi; S Barbieri; A Priori
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-09-18       Impact factor: 5.067

5.  Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates.

Authors:  Francesco Benedetti; Barbara Barbini; Mara Cigala Fulgosi; Cristina Colombo; Sara Dallaspezia; Adriana Pontiggia; Enrico Smeraldi
Journal:  J Clin Psychiatry       Date:  2005-12       Impact factor: 4.384

6.  Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression.

Authors:  C Colombo; F Benedetti; B Barbini; E Campori; E Smeraldi
Journal:  Psychiatry Res       Date:  1999-06-30       Impact factor: 3.222

7.  Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.

Authors:  Lori Altshuler; Trisha Suppes; David Black; Willem A Nolen; Paul E Keck; Mark A Frye; Susan McElroy; Ralph Kupka; Heinz Grunze; Jörg Walden; Gabrielle Leverich; Kirk Denicoff; David Luckenbaugh; Robert Post
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

8.  Standardised Assessment of Personality - Abbreviated Scale (SAPAS): preliminary validation of a brief screen for personality disorder.

Authors:  Paul Moran; Morven Leese; Tennyson Lee; Paul Walters; Graham Thornicroft; Anthony Mann
Journal:  Br J Psychiatry       Date:  2003-09       Impact factor: 9.319

9.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382

10.  A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression.

Authors:  Brian P Brennan; John Eric Jensen; James I Hudson; Caitlin E Coit; Ashley Beaulieu; Harrison G Pope; Perry F Renshaw; Bruce M Cohen
Journal:  J Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.153

View more
  1 in total

1.  Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant.

Authors:  Manish Kumar Jha
Journal:  Int J Neuropsychopharmacol       Date:  2022-01-12       Impact factor: 5.176

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.